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ABSTRACT

Mass Spectrometry Based Proteomics and Lipidomics Studies
Huan Kang
Department of Chemistry and Biochemistry, BYU
Master of Science
Mass spectrometry has emerged as having a vital role in various applications to
biochemical fields. In this thesis, we have utilized a variety of mass spectrometry techniques
for both bacteriophage proteomics and colostrum and milk lipidomics studies.
Our first study was the proteome characterization of Great Salt Lake bacteriophage
NS01 with SDS-PAGE GEL to separate the viral proteins and high performance liquid
chromatography (HPLC) coupled with an LTQ Orbitrap to identify the proteins after in-gel
digestion. In this project, we have successfully identified 11 proteins with high confidence,
p-values < 0.01, including coat protein gp88 with a coverage of 91% and tail protein gp86
with a coverage of 40.96%, which facilitated the classification of NS01 as a T7-like phage.
Our second study was the discovery of colostrum and milk biomarkers that can be used
to predict the likelihood of development of production-related metabolic diseases (PRMDs)
in dairy cows through a lipidomics approach. In this study, an electrospray ionization,
time-of-flight mass spectrometer was applied to lipid profiling, quantification and significant
biomolecule selection. A Q-Star quadrupole, orthogonal time-of-flight mass spectrometer
and an Agilent 6530 accurate-mass quadrupole/time-of flight mass spectrometer were both
used for lipid biomarker fragmentation and identification. According to linear discriminative
statistical modeling, three panels of biomarkers were defined. A combination of 2 milk lipid
predictors, including DG18:0/18:0 and TG 18:0/18:0/18:1, provided PRMD predictions with
75.0% sensitivity at 90.0% specificity. A combination of 3 colostrum lipid predictors,
including TG16:0/18:1/18:3, DG16:0/16:0 and C40H60NO, provided PRMD prediction with
90.0% sensitivity at 86.4% specificity. Furthermore, a combination of 7 colostrum and milk
biomarkers, including calculated differences between ‘shared’ markers found to be
significantly different in both colostrum and milk, provided a predictive sensitivity of 87.5%
at a specificity of 100%. Thus, three panels of lipid biomarkers have been discovered in 1-4
day postparturient dairy cow colostrum and milk that can be used to predict resistance or
susceptibility prior to onset of clinically apparent PRMDs. These novel lipids could be used as
important diagnostic predictors in the future. Therefore, mass spectrometry based
proteomics and lipidomics approaches have been efficient tools in the biochemical research
described in this thesis.

Keywords: proteomics, bacteriophage, lipidomics, mass spectrometry, biomarker,
production-related metabolic diseases
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Chapter 1 Introduction

1.1 Mass spectrometry based lipidomics analysis
1.1.1 Lipid biomarkers overview
Lipids represent the largest and most diverse set of biomolecules. Their unifying
characteristic is their hydrophobicity. Lipids have been known to have structural importance,
but more recent research suggests many are biologically important active compounds
mediating and regulating many cellular and systemic processes. Lipids are not directly
genetically regulated. They are generated and metabolized by enzymes that are affected by
the environment through such factors as nutrition and temperature. As is currently known,
changes in lipids are seen in nearly all diseases states, including cardiovascular diseases,
metabolic diseases like diabetes mellitus, obesity, Alzheimer’s disease, arthritis, asthma,
cancer, and importantly they may play significant roles in the pathophysiology of such
diseases (Table 1). Useful biomarkers may result from downstream responses to the disease,
but may also be upstream activators, regulators or general contributors to the disease.
Therefore, specific lipids or groups of lipids may become clinically relevant biomarkers that
can be used to specifically predict the risk for or can be used to diagnose particular diseases.
Lipids have been researched as potential biomarkers in many diseases using various
biological samples. For instance, the sphingolipidome has been shown to provide potential
biomarkers for early-stage Alzheimer disease1, type 1 diabetes2, neurodegenerative disease3,
etc. Some lipids such as polyunsaturated fatty acids4, triglycerides5, glycerophospholipids6,
sphingolipids6, and sterols6 have participated in or been altered by metabolic disorders, and
1

Diseases

Lipids

Samples

Ref

Obesity

Ceramide, lysophosphatidylcholine, free

Plasma

7

Plasma

7 9

Cardiolipin, TG and cholesterol esters

A549 cells

10

Phospholipids, sphingolipids and related

Serum, brain

11 12 1 13

compounds, sulfatide

autopsy

14

Phosphatidylcholine, total cholesterol,

Human breast

15 16

low-density lipoprotein cholesterol

tissue, plasma

Lysophosphatidic acid,

Plasma

17

Serum, mice

18 19

Plasma

4

，8

fatty acids, TG
Diabetes

Lysophosphatidylcholine, free fatty acids,

,

TG, cardiolipin
Mitochondrial
dysfunction
Alzheimer

Breast cancer

Ovarian cancer

, ,, ,

,

lysophophatidylinositol,
sphingosylphosphorylcholine,
lysophosphorylcholine,
lysophospholipids
Asthma

Phosphatidylcholine, leukotriene B4,

,

prostaglandin D2
Hepatic

Polyunsaturated fatty acids,

steatosis

glycerophospholipids, sphingolipids, sterols

Table 1. Lipid abnormalities in associated diseases. TG: triglycerides
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as such, are potential phenotypic or disease biomarkers.
Despite more research studies regarding protein biomarkers than lipid biomarkers,
recent advances in lipid profiling, quantitative analysis and bioinformatics methods provide
an opportunity to explore and define new roles for lipids and allow for them to be further
characterized as biomarkers in order to predict or diagnose a range of diseases. In addition,
in comparison with proteomic approaches, lipids are more stable, easier to handle, and may
also provide a more economically efficient test for use in clinical practice than would protein
mass spectrometry (MS) methods.

1.1.2 Mass spectrometry as a tool for lipidomics
By obtaining profile patterns of lipid molecules through MS analysis, metabolic changes
can be observed under specific circumstances. Several such methods have been carried out
including global20, focused21, and targeted22 lipidomics using mass spectrometry.
Global lipidomic methods are applied to measure all or as many analytes as possible
that are contained within extracted lipid samples without background information on any
specific lipids or their fragments23. Put another way, this approach is unbiased and often
considers hundreds of lipids, sometimes many more, in the discovery of biomarkers. Mass
spectrometers with high resolution are always used for lipids profile studies to allow for the
unambiguous resolution and measurement of all species observed. By combining liquid
chromatographic separation with tandem mass spectrometry (MS/MS), fragmentation can
be carried out, allowing for more information about the components that make up specific
lipids, potentially identifying the specific lipid species. With the use of appropriate added
3

reference lipids, reasonably good quantification can also be determined.
A focused lipidomics approach aims to detect molecules of a particular lipid class by
focusing on specific fragments or neutral losses between fragments that are highly
associated with a single lipid subgroup24. Through this method, lipids that are present at
abundances normally below the MS detection limit can also be detected, which helps to
overcome MS ion suppression issues. Taking phospholipids as an example, product ion
scanning at m/z 184 could be used to select for choline-containing phospholipids in the
positive ion mode. Furthermore, neutral loss scanning at m/z 141, 185, 189 and 277 could
be used for detection of phosphoethanolamine (PE), phosphatidylserine (PS),
phosphoatidylglycerol (PG), and phosphatidylinositol (PI) species, respectively.
Targeted methods can be applied to choose one or a few specific molecules by precisely
selecting m/z values for the lipid(s) of interest or by selection of its specific fragment ions.
Through a targeted method, lipids can be either accurately quantified based their m/z values
and their specific fragment ions or characterized by their fragmenting ions. The
fragmentation information of the peak of interest can be obtained through specific product
ion scanning as in other multiple reaction monitoring protein approaches.
In our experiments, we used a comprehensive or global lipidomics approach by means
of electrospray ionization mass spectrometry (ESI-MS) to find peaks of interest (significant
statistically, quantitatively different lipids) based on abundances between disease and
control samples, and a targeted MS/MS method in order to fragment and further chemically
characterize peaks of interest.

4

1.1.3 Electrospray ionization mass spectrometry (ESI-MS) as a tool for determining lipid
identity
After the determination of lipids of interest, identification of the lipids is important in
order to fully understand selected biomarkers and their role in biological functions. This was
briefly discussed previously, but will be developed further in this section.
Tandem mass spectrometry involving ion-trap, triple quadrupole, or hybrid instruments
such as quadrupole-time-of-flight, linear ion trap quadrupole are normally used for lipid
identification with electrospray ionization as the ion source. Characterization of individual
lipids using ESI-MS requires knowledge of the m/z value for the lipid of interest. Then
fragmentation of the targeted peak or a target peak list based on m/z values is conducted
through product-ion analysis after collision-induced dissociation (CID)25. By adjusting the
collision energy26, the abundance of the product ions of lower molecular mass will be
different, which is useful for identification of the location of double bonds in fatty acyl chains.
Optimal conditions for CID are determined by systematic investigations according to
individual peak.
Multiple sector mass spectrometry instruments and MS-MS techniques can be applied
and combined for lipid biomarker(s) characterization. For example, in our studies, both
QSTAR and Qq-TOF27 instruments were used for biomarker characterization. The QSTAR can
select the targeted peak with low resolution, unit resolution and high resolution. However, it
has a lower sensitivity and resolution power compared with Qq-TOF. Thus, the QSTAR may
have a hard time detecting the peak of interest if it has a low abundance. As for the Qq-TOF,
it can detect low abundance peaks.
5

Extensive MS-MS characterizations of the most common lipid classes, including mass
spectra, have been published in the literature. Taking triacylglycerols as an example, the sn-1,
sn-2 or sn-3 component of triacylglycerols can be determined based on neutral loss values
with fragmentation as recorded in the product-ion scan. Triacylglycerols are neutral
hydrophobic lipids defined as fatty acid triesters of glycerol. Therefore, positive ions such as
ammonium acetate, sodium, and lithium that can form positive adducts with neutral lipids
are always added to the solvents in order to produce lipid ions that can be detected in
positive ion mode of mass spectrometry.
Product-ion mass spectra of ammoniated triacylglycerol species ([M+NH4]+) at an m/z
value of 906.83 after CID at 25 eV yielded product ions as shown in Figure 1, which can be
informative for structural characterization. The fragment ion at [M+NH4-17]+ at 889.81,
arising from the loss of ammonia (NH3) from the ammoniated triacylglycerol species, was
observed and always present in the spectra (Figure 1a). The fragments shown in the spectra
with m/z values of 605.54 and 607.55 represent diacylglycerol (DG) fragments 18:0/18:1 and
18:0/18:0. By searching the LIPIDMAPS28 database, the product ion scan provided the
probable structure as TG 18:0/18:0/18:1 for precursor ion 906.83.
High resolution and mass accuracy are required for reliable identification of lipids.
Fragment ions of polar headgroups or specific neutral losses from each class of
phospholipids and glycerolipids are also very important for identification of each different
category of polar lipids. In some cases, MS3 or MS4 (multiple steps of mass spectrometry
selection with some form of fragmentation occurring in between the stages) may be
important in order to obtain reliable identification.

6

(a)

(b)
Figure 1. Targeted MS/MS analysis of Qq-TOF mass spectrometry. (a) product-ion spectra of m/z 906.83 [TG
(18:0/18:0/18:1)+NH4]+, (b) representation of the two most abundant diacylglycerol fragments at 605.55 and
607.56.
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1.1.4 Comparison and overview of lipid extraction techniques
Due to different polarities, lipids dissolve in solvents based on the relative strengths of
the interactions between the solvent and either the hydrophobic or the hydrophilic regions
of the lipid molecules. For instance, lipids of low polarity, such as triacylglycerols or
cholesterol esters, are very soluble in non-polar hydrocarbon solvents. Organic solvents are
always used for lipid extraction from tissues, cells, and other biological fluid29. Here, the
three main lipid extraction methods are discussed, including the Folch method, the Bligh and
Dyer extraction, and a newer version of lipid extraction using methyl-tert-butyl ether30.
First, according to the Folch31 total lipid isolation method, lipids are extracted by
homogenizing a tissue with 2:1 chloroform-methanol (v/v) solution, then the homogenate is
filtered and the filtrate further purified with a 5 volume addition of water.
Second, a mixture of chloroform:methanol:water in the proportion of 1:2:0.8 and
2:2:1.8 (before and after dilution, respectively) is used for lipid extraction, particularly for
phospholipids as described by Bligh and Dyer31. This method is recommended for large
samples with a high proportion of endogenous water.
Third, for extraction by methyl-tert-butyl ether30 (MTBE), 1.5 mL methanol is added to a
200 µL sample aliquot in a glass tube, and the tube is vortexed. 5 mL of MTBE is added and
the mixture placed on a shaker for 1 hr at room temperature. Then, 1.25 mL of MS-grade
water is added for full separation of the aqueous layer and organic layer.
There are reviews comparing the extraction efficiency between these distinct organic
extraction methods29. For instance, a comparison of the Folch versus Bligh and Dyer method
was done on marine tissues and meat products32, which showed that the efficiency of
8

extraction was determined by the amount and percentage of lipids in the sample. Previous
studies have proven that for samples containing more than 2% lipid, the Bligh and Dyer
method significantly underestimated the lipid content, and this underestimation increased
significantly with increasing lipid content of the sample33.
For the MTBE method, the lipid layer is on top, which could help minimize carry-over of
proteins. Another advantage of the MTBE lipid isolation method is that there is less toxicity
in the extraction process by omitting chloroform as an organic solvent. Researchers have
also made modifications based on the classifications of the lipids of interest. Different
solvents are necessary to extract different lipids optimally. Plus, lipid extraction is carried out
differently according to the nature of the biological specimen. For example, plant tissues are
normally treated with isopropanol in order to denature the botanical enzymes prior to lipid
extraction.
In our experiments, we used a modified Bligh and Dyer method with
chloroform:methanol:isopropanol in a 2:1:1.25 ratio for lipid extraction from colostrum or
milk samples as opposed to the standard method which uses
chloroform:methanol:water in the proportion of 1:2:0.8 and 2:2:1.8 (before and after
dilution, respectively). In addition, water was later added to allow for full separation of the
aqueous layer and organic layer. Thereafter, 10 mg of the cream layer (the thick white or
pale yellow fatty liquid that rises to the top when either colostrum or milk is left to stand,
and composed of mainly lipids) was used for lipid extraction, which contained greater than 2%
lipid. Therefore, it was necessary to increase the chloroform portion to two fold compared
to the original Bligh and Dyer extraction solvent mixture in order to have a fuller recovery of
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lipids.

1.1.5 Mass spectrometry as a predictive tool for production-related metabolic diseases
(PRMDs) in dairy cows
Over the past 100 years, the United States dairy industry has experienced a sharp
reduction in the total number of cows and at the same time a nearly six-fold increase in
average milk production per cow, with a substantially greater overall annual milk production.
This has led to dairy cows being at an increased risk of developing production-related
metabolic diseases (PRMDs). PRMDs are due to certain cows’ physiologic inability to cope
with the metabolic demands of such high milk production. These health problems occur
most often during the transition period (3 weeks pre-partum to 3 weeks after parturition),
with the highest clinical incidence occurring within two weeks postpartum. Recently, PRMDs
in dairy cows have been broadly defined to include conditions such as hypocalcemia,
hypomagnesemia, ketosismana, hepatic lipodosis, abomasal displacement, laminitis,
retained placenta, and other disorders that occur during the transition period.
Over the past 20 years, there has been great interest in the impact that PRMDs have on
dairy farm profitability, and in understanding what contributing factors and/or
predisposition for such diseases exist, to eliminate and minimize economic losses. Although
it is known that the highest incidence for most PRMDs occurs within the first 60 days in milk
(DIM), the multifactorial disease incidence has not been altered by transition diets,
manipulating prepartum dietary cation anion balance34, and over conditioning avoidance35.
The nutritional and metabolic status36,37 of certain animals, combined with a poor
10

physiologic adaption38 to the negative energy balance experienced during the rapid rise in
milk production with the onset of lactation, is associated with the development of PRMDs39.
Although PRMDs usually effect a subset of cows within a dairy herd, the insidious nature and
economic impact these health problems cause warrants a better means of earlier detection.
Accurate biomarkers that could be easily applied to an animal substrate would provide an
important diagnostic and management tool to predict individual cow resistance or risk for
PRMDs while the animal is clinically normal. This method could be used during the
peripartum period to provide an economical method to identify cows that are resistant or
susceptible to PRMDs, for retention, breeding, early treatment intervention, or culling
decisions to increase profit margins.
Biochemical analytes have been previously explored to predict the development of
PRMDs in dairy cows including the measurement of serum non-esterified fatty acids (NEFA)40,
β-hydroxy-butyrate (BHBA) and calcium concentrations41 during the final week of gestation

or the first and second week postpartum, to provide useful information for herd health
monitoring and culling risk42. The effectiveness of their predictive ability was summarized by
Ospina et al (2010) as shown in Figure 2. Additionally, the serum concentrations of NEFA at
calving have been shown to be positively correlated with a negative energy balance and the
incidence of certain peripartum diseases43. Hyperketonemia in the blood during the first
week of lactation, on the other hand, appeared to be an important risk factor for the
subsequent development of clinical ketosis, metritis, and displaced abomasum44. Serum
cholesterol concentration was shown to have a greater decrease during the transition period
in cows that developed disease45 PRMDs.
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(a)

(b)
Figure 242. Prediction efficiency using NEFA and BHBA as predictors for transition diseases risk in dairy cows. (a)
Information on thresholds from receiver operator characteristic curves for NEFA concentrations as predictors of
displaced abomasum. (b) Information on thresholds from receiver operator characteristic curves for BHBA
concentrations as predictors of displaced abomasum in animals sampled postpartum (n =1318). Results from
Table 2 and Table 4 Ospina et al (2010). BHBA = beta hydroxybutyris acid, NEFA = non-esterified fatty acid. From
Ospina et al (2010) used with permission.
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Figure 3. Schematic of milk fat synthesis and secretion in ruminants46. From Chilliard et al (2009) used with
permission
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Therefore, lipids, including NEFA, BHBA, and cholesterol, have shown some promise as
biomarkers of PRMDs. The objective of the current research was to detect accurate
biomarkers that can predict PRMD resistance or susceptibility, and was based on the
presence of lipids in colostrum and early milk secreted by the cow’s udder (Figure 3, from
Ospina et al (2010), a schematic description of the milk fat synthesis pathway), to define the
lipid status broadly through a mass spectrometry based lipidomics approach. With
MS techniques, and may potentially be applied as biomarkers. Our findings were promising
and may further suggest biological pathways involved in or altered by PRMDs.

1.1.6 Summary
In summary, sample preparation for mass spectrometry-based lipidomics analysis
sample is easier compared to sample preparation for proteomics analysis. However,
lipidomics fragmentation analysis is not as advanced as proteomics, and it can be
challenging to do the lipid MS spectral analysis, to not only discover useful biomarkers, but
to also achieve these markers’ identification.
In this project, we focused on lipid biomarker discovery to identify peripartum dairy
cows at risk for the later development of PRMDs using a lipidomics approach. If such
markers could be found, given that they are present prior to development of PRMDs, they
may allow therapeutic intervention for the prevention of PRMDs. Lipids in colostrum or milk
samples were collected and evaluated for this study after extraction by the modified Bligh
and Dyer method. Several individual candidate biomarkers were found in colostrum and milk.
Statistical modeling of the individual markers resulted in 3 panels of biomarkers capable of
14

identifying a very high percentage of at-risk, as well as PRMD resistant animals. One set of
biomarkers had 87.5% sensitivity and 100% specificity based on our data set. The sample
collection was done by members of Dr. Beverly Roeder’s lab. Among the undergraduate
students Holly Martin, Kory Brown, Austin Cook, Alice Huang, and Evan Buckmiller from the
Department of Biology and Department of Chemistry and Biochemistry (Brigham Young
University) made substantial contributions to the collection, sorting, and processing of these
samples, including optimizing the various processing protocols. Members of my lab (Dr.
Steven Graves) worked on sample processing and instrument analysis and methodology. One
of the undergraduate students, Chris Lau, helped write a micro program within Excel that
facilitated our processing the MS data analysis. Dr. Dennis Eggett from Department of
Statistics, Brigham Young University, helped us with statistical modeling to successfully
identify different panels of biomarkers. Graduate students Swati Anand, Komal Kedia and
Ying Ding from Dr. Steven Graves’s lab advised and assisted with MS fragmentation and lipid
identification of the relevant biomarkers. This proved to be a substantial project requiring
both my committed efforts as well as the collaborative efforts of many others to accomplish
it.
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1.2 Mass spectrometry based viral proteomics study
1.2.1 Viral proteomics
Viruses have long been studied for their pathology, associated disease, as model
systems for molecular processes and as tools for identifying important cellular regulatory
proteins and pathways. Most viral research has been focused on positive and negative gene
regulation, repressor operator interactions, DNA replication, transcriptional elongation and
termination, etc. However, with the development of high-throughput proteomics methods,
the protein composition of virions, the structure and protein interactions of viral proteins,
and the effects of viral infection and individual viral proteins on the cellular proteome can be
obtained.
Determining the global protein composition of a specific virus particle normally involves
multiple steps including pure virus preparation, detergent denaturation, electrophoretic
separation, and identification of protein bands by mass spectrometry where mass
spectrometry is a valuable tool in structural and functional viral proteomics. Dennis Hruby’s
lab47 has obtained a detailed knowledge of the Pox vaccine viral proteome through sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) + LC-ESI-Q-TOF MS, SDS-PAGE
+LC-ESI-QIT MS, HPLC+ LC-ESI-QIT MS, LC-ESI-Q-TOF MS, MALDI-TOF/TOF MS analysis
methods, and were able to identify 63 proteins. By using SDS PAGE and LTQ- Orbitrap,
Kerstin Radtke’s group were able to identify a total of 67 structural and nonstructural viral
proteins of the Herpes Simplex Virus type 1 (HSV1)48 and identified 90 novel
phosphorylation sites and 10 novel ubiquitination sites on different viral proteins. Therefore,
a comprehensive mass spectrometry based viral proteomics study has been proven to be
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very effective. By comparison with complementary data from genome sequencing, cryo-EM
and image reconstruction, a new dimension to viral protein structure and function can be
obtained.
Mass spectrometry based viral protein studies have enabled a more comprehensive
characterization of virions and of virus-virus and virus-host interactions involved in infection
and pathogenesis. Viral proteomics has been a promising tool to survey antigenicity of the
influenza virus49 and for understanding virus tropism50. Moreover, the development of viral
proteomics might also provide potent tools for diagnosis, and could generate novel insights
into the therapeutics of virus-induced infectious diseases.

1.2.2 Summary
As is known, a virion, i.e. an entire virus particle, consists of an external protein shell
called a capsid and having an inner core containing nucleic acid. The core confers infectivity,
and the capsid provides specificity to the virus. Extremophilic viruses are the viruses that can
tolerate environmental limits beyond what most living organisms endure in terms of
temperature, pH, salinity, desiccation, hydrostatic pressure, radiation, anaerobiosis, etc.
Thus far, several extremophilic viruses have been characterized. The continuous attempts to
isolate and to study viruses that thrive in extreme environments are needed to address such
questions as the origin, activity, or importance of the in situ microbial dynamics. However,
this topic appears to open a new window on an unexplored part of the viral world.
In this project, three groups were involved, including Dr. Matt Domek‘s lab efforts in the
collection and cultivation of the NS01 virions. Virion imaging and structural modeling studies
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were achieved by Dr. David Belnap’s lab, and our lab and specifically my efforts, were
focused on NS01 protein characterization. In this thesis, I will talk about Dr. Domek’s and Dr.
Belnap’s work for reference and clarity, but discuss my protein characterization studies in
much greater detail.

.
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Chapter 2 Sequence and structural characterization of Great Salt Lake Bacteriophage NS01,
a turreted T7-like virus with flexible HK-97 subunits
2.1 Introduction
Studies of virus populations in the Dead Sea indicate that viruses in extreme
environments play a predatory role in recycling organic matter and regulating bacterial host
populations where eukaryotic predators are rare 51. Thus far, six extremophilic viruses have
been studied by cryogenic electron microscopy (cryo-EM): SH1 52, STIV 53, STIV2 54, CW02 55,
HVTV-1 56, and HSTV-2 56. Four of the extremophilic viruses studied via cryo-EM to date have
shown unusual turret appendages at each five-fold vertex; however, the purpose of such
turrets remains unknown. Thus, the ubiquity of phages in aquatic environments 57 and the
lack of structural data about those in extreme environments suggest the need and potential
for more research in understanding extremophilic viruses.
Bacteriophage NS01 is a tailed, dsDNA extremophilic virus isolated from the Great Salt
Lake and infects Salinivibrio costicola. Another halovirus, CW02, was recently reported to
infect a Salinivibrio costicola-like bacterium, SA50, and characterized by cryo-EM 55. CW02 is
a dsDNA, tailed virus that belongs to the Caudovirales order and Podoviridae family of
phages, as defined by its short, non-contractile tail and icosahedral head 55. Interestingly,
CW02 contains flexible turret structures at each 5-fold axis, much like other extremophilic
viruses such as SH1 52, STIV 53, and STIV2 54.
The structural and sequence analysis of NS01 revealed its relationship to CW02 and
other dsDNA, tailed phages. Negative stain microscopy images suggest that NS01 is
morphologically similar to viruses of the Podoviridae family and that it also has turrets at the
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5-fold vertices similar to those found in SH1 52, STIV 53, and STIV2 54 (Figure 2A). PSI-BLAST
sequence analysis also showed a relationship between NS01 and Enterobacteria phage T7 58
and T7-like phages such as Vibrio phage ICP3 59, Vibrio phage VpV262 60, Enterobacteria
phage N4 61, and Salinivibrio phage CW02 55. A 22 Å cryo-EM reconstruction of NS01
revealed T=9 icosahedral symmetry in the capsid head, prominent turret structures at each
5-fold vertex, and showed that the HK97-like fold fit within the capsid density, supporting
the observation that dsDNA, tailed phages contain a common ancestral HK97-like fold.

2.2 Materials and methods
Cultivation and purification: Cultivation and purification were done in the laboratory of
Professor Matt Domek. In brief, host bacteria and bacteriophage were isolated from the
Great Salt Lake, Utah, USA. PCR was applied for amplification of host bacteria and
approximately 1350 base pairs were sequenced (Idaho State University, Molecular Research
Core Facility, Pocatello, Idaho, USA) and queried against the GenBank database using the
BLAST search tool. The isolate was found to share 99% sequence identity with Salinivibrio
costicola subsp. costicola strain ATCC 33508 (NR_027590.1). NS01 was further isolated by
use of a plaque assay of filtered GSL water. The bacteriophage was further purified by
isopycnic ultracentrifugation (64% CsCl w/v) at ~125,000 x g for 24 hours at 4 oC.

Genome isolation and sequencing, and sequence analysis: Genomic DNA was sequenced at
the Brigham Young University DNA sequencing Center using a Roche Genome Sequencer FLX
Instrument and employing the GS FLX Titanium Sequencing XLR70 kit (Roche Diagnostics
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Corporation, Indianapolis, Indiana, USA) by Dr. Belnap’s lab. Putative open reading frames
(ORFs) of the NS01 genome were determined using GeneMarkS 62 and numbered according
to whole-genome homology with bacteriophage PA11 63.

Electron microscopy and image reconstruction, and structural modeling: For negative
staining and cryo-EM, purified NS01 was prepared for microscopy as previously described
(33) and was done in Dr. David Belnap’s lab. Structural studies were accomplished by
Professor David Belnap’s lab. All surface renderings of the reconstruction were done at 1-σ
contour level, which was defined by the sum of the average and standard deviation of map
densities. Individual protein subunits were manipulated by eye to obtain a final fitting.

NS01 Desalting: 100 kDa filter (Sartorius Stedim, Bohemia, New York, USA) was applied for
NS01 virion desalting. Virion in solution was loaded onto a 100 kDa filter and centrifuged at
1000 min-1. Double distilled water was used for virion buffer exchange for 3 times and
further transferred to a new 100 kDa filter for complete desalting. Virions were collected by
centrifuging at highest speed through the filter with a new centrifuge tube.

Protein separation by SDS-PAGE and in-gel digestion: NS01 virions were subjected to sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to separate individual
proteins. The gel of 4-15% polyacrylamide, containing 10 wells (Bio-Rad Laboratories, Inc.,
USA) was stained using Coomassie blue reagent, after which individual gel bands were
excised then shredded by spinning gel fragments through micropipette tips. Proteins were
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prepared for analysis by mass spectrometry using a modified filter-aided sample preparation
(FASP) protocol, adapted from the protocol of Dr. Mann’s group64.

Briefly, the gel fragments were destained using a 1:1 mixture of acetonitrile:8M urea, 0.1M
Tris-HCl (pH 8.5). The denatured proteins were subsequently reduced with 0.1M
dithiothreitol in UA buffer (8M urea, 0.1M Tris-Cl, pH 8.5), then carboamidomethylated with
50 mM iodoacetamide in UA buffer. Each solution was washed by filtration through a 10 kDa
molecular weight cutoff filter (Sartorius Stedim, Bohemia, New York, USA). The urea and
iodoacetamide were then replaced by 50 mM ammonium bicarbonate. Proteins were finally
digested by sequencing grade trypsin (Promega, Madison, WI, USA) overnight at 37 oC and
then acidified by addition of formic acid (Rockford, IL, USA) to a 1% v/v concentration in the
final solution.

Mass spectrometry: Acidified peptide samples were loaded onto a 75 micron x 15 cm
nanoAquity C18 column (Waters Corporation, Milford, Massachusetts, USA) and eluted by a
300min binary gradient of Optima grade Solvent A (5% acetonitrile, 0.1 % formic acid) and
Optima grade Solvent B (0.1% formic acid, 99.9% acetonitrile) (Thermo Scientific, San Jose,
California, USA) at a rate of 325 nL/min composed of the following steps: From a baseline at
98% Solvent A, a 208-minute linear gradient to 63% A , a 23-minute gradient to 1.5% A,
followed by a 20-minute return to a 98% A baseline for 27 minutes.
Column effluent was directed to a nanoESI spray source on a LTQ-Orbitrap XL (Thermo
Scientific, Waltham, Massachusetts, USA). Data dependent acquisition was performed by
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coupling a 60,000 resolution survey scan in the Orbitrap with up to the top ten subsequent
CID MS/MS scans, acquired in the ion trap (signal threshold of 500, normalized collision
energy of 35%, isolation width of 2 m/z, with a two-count dynamic exclusion in a
three-minute window). A lock mass of the cyclomethicone N5 ions generated in the
electrospray process from ambient air (m/z 371.101230) was used as an internal mass
calibration standard65.

Data analysis: MS/MS spectra were converted to Mascot generic format by the MsConvert
program (http://proteowizard.sourceforge.net/pubs.shtml). Mascot searching was queried
against a database of ORFs derived from the NS01 genome. The peptide search space was
expanded by concatenating the NS01 database with a comprehensive database of the
Escherichia coli ATCC 8739 proteome (GenBank accession no. YP_001723016.1) and a
reverse decoy version of the same database. Results were filtered to provide a 1% false
discovery rate (FDR) confidence at the peptide level.

2.3 Results and discussion
Proteins in the head structure module. We identified gp88 as the major capsid protein
because of its high abundance in the NS01 SDS-PAGE analysis and LC-MS of the gel band
(Figure 4). PSI-BLAST of gp88 resulted in matches with P22-like coat proteins in Clostridium
phage phiCP26F and Clostridium phage phiCP13O with E-values ≤ 1e-18. Pairwise sequence
analysis of gp88 and the major capsid proteins of T7, HK97, and P22 resulted in only 19%,
15%, and 20% identity, respectively. However, secondary structure predictions by the Phyre
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(kDa) MW

NS01(10 µl)

NS01(3 µl)

120
85

50
35
25

91/68

86/78
72/69
88

88/73

81
77

20
82

Figure 4. Protein composition of mature wild-type NS01 particles determined by SDS-PAGE and identified by
LC-MS/MS. 4 pairs of gene products have similar sizes and were not separated in the gel including gp91/68,
gp86/78, gp72/69, gp88/73. See Table 2 for properties of gene products. Lane MW contains molecular size
markers. MW: molecular weight marker in kDa; NS01 (10 µL): 10µL of samples were loaded onto the gel; NS01
(4 µL): 4µL of samples were loaded onto the gel.
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Protein Fold Recognition Server 66 predicted the structure of gp88 to most closely resemble
the major capsid protein fold of prochlorococcus2 cyanophage p-ssp7, T7, P22, and HK97
with 100%, 100%, 99.5%, and 98.1% confidence, respectively. These results are consistent
with the observation that the HK97 fold is more conserved than is its sequence among
T7-like phages.

Proteins in the tail structure module. Putative tail structure proteins were predicted to be
leftwards of the head structure module in the genome, characteristic of T7-like phages60. A
PSI-BLAST search suggested that gp79 and gp86 are putative tail proteins.

In addition, several large ORFs are found in the NS01 genome at locations reasonably
predicted to encode tail-associated proteins. For example, trimeric structures of coiled-coils
and β-helices are a common motif in tail-associated proteins, such as the tail-spike protein
of P22 (homotrimers of β-helices)67 and tail fibers of bacteriophage T7 (triple-stranded
coiled-coils)68. Thus, the presence of coiled-coils and β-helices in candidate ORFs within the
putative tail structure module was examined. The BetaWrapPro program predicted
right-handed beta-helix motifs in gp81, gp82, and gp85, and the COILS program predicted a
coiled-coil motif in gp78.
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Figure 5. HPLC Orbitrap-LTQ chromatography (top) and ion map (bottom) of gp88.
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Figure 6. Mascot result output of gp88, the major capsid protein, which had a score of 1744 and a sequence
coverage of 91%.
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ORF

Unique peptides

% Coverage

Putative function &
structure prediction

gp91

18

37.48

possible N4-like portal
protein

gp86

15

40.96

tail fiber

gp72

21

63.24

NA

gp88

28

91 (10 uL)

coat protein

gp77

5

48.79

NA

gp88

20

73.74 (3 uL)

coat protein

gp78

16

54.29

coiled-coils (COILS)

gp68

19

36.12

NA

gp69

14

37.62

NA

gp81

10

27.2

beta-helix
(BetaWrapPro)

gp82

5

28.39

beta-helix
(BetaWrapPro)

gp73

4

13.59

NA

Table 2. NS01 protein identification results from Mascot found by running against the NS01 ORF database.
Trypsin was used for a bottom-up proteomics approach. Unique peptide identification and the percentage of
amino acid sequences observed were included in the table as a reference for the identification confidence.
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Chapter 3 Discovery of colostrum and milk biomarkers predictive of production-related
metabolic disease risk through a lipidomics approach
3.1 Abstract
Production-related metabolic diseases (PRMDs) are a set of debilitating disorders occurring
in certain early lactation dairy cows. Animals could potentially be rescued prior to clinical
signs of disease if it were known that they were at risk. In order to identify valuable lipid
biomarkers, predictive of PRMDs in asymptomatic postpartum dairy cows, samples of
colostrum (20 cases, 22 controls) and post-partum day 4 milk (16 cases, 20 controls) were
collected and analyzed for lipid composition and specific lipid abundance using mass
spectrometry. A modified Bligh and Dyer lipid extraction method, followed by direct
injection electrospray ionization-mass spectrometry (ESI/MS) approach, was used for this
lipidomics study. Many lipids were differentially expressed in both colostrum and milk as
determined in a comparison between cows that later developed PRMDs to cows having no
clinical signs of health problems. After statistical modeling of these several candidate
markers, three panels of biomarkers were developed. A combination of 2 milk lipid
biomarkers including a diglyceride (DG 18:0/18:0) and a triglyceride (TG 18:0/18:0/18:1)
provided predictions with 75.0% sensitivity at 90.0% specificity. A combination of 3
colostrum lipid biomarkers including TG 16:0/18:1/18:3, DG 16:0/16:0 and an unclassified
lipid C40H60NO provided predictions with 90.0% sensitivity at 86.4% specificity. Furthermore,
a combination of 7 colostrum and milk biomarkers, including calculated differences between
‘shared’ markers found to be significantly different in both colostrum and milk, provided a
predictive sensitivity of 87.5% at a specificity of 100%. Therefore, three panels of useful,
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predictive, lipid biomarkers have been discovered in peripartum colostrum and milk
sampling via lipidomics that can identify at risk cows days to weeks prior to onset of PRMDs.

Keywords: Production related metabolism; lipidomics; mass spectrometry; colostrum; milk;
biomarker
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3.2 Introduction
Production-related metabolic diseases (PRMDs) in dairy cows have been and continue to be
a costly problem for the dairy industry. Different phenotypes of PRMDs have been
documented, including hypocalcemia (commonly known as milk fever), displaced abomasum
(DA), ketosis, fatty liver syndrome, and retained placenta amongst the most common
disorders. These health problems may present with decreased milk production, altered milk
composition, reduced reproductive capacity, shortened life expectancy and lower cull value,
resulting in both animal and economic loss. Interventions for PRMDs are currently available
after onset of clinical signs, but result in additional economic losses associated with
medication and labor costs. Identifying animals that will have these complications early
enough to prevent onset of PRMDs has not been possible previously.

PRMDs are multifactorial and the causes are complex. The different phenotypes of PRMDs
have been documented based on the clinical signs of disease manifested. However, although
a variety of health problems have been identified, they are inter-related physiologically, and
not distinct, independent entities69,70. Acute milk fever results from hypocalcemia,
characterized by reduced ionized blood calcium levels, and must be treated as a medical
emergency71. Displaced abomasum, in contrast, has been shown to be preceded by ketosis,
and is often accompanied by subclinical hypocalcemia72. Ketosis is a metabolic process that
occurs when the body does not have enough glucose to maintain normal cellular energy
production73. In consequence, stored fats are broken down and mobilized to meet energy
needs, resulting in elevated fatty acids and a build-up of organic acids called ketone bodies
within the circulation. Fatty liver syndrome in dairy cows has been shown to occur when the
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synthesis of triacylglycols (TGs) is higher than their export and appears to be associated with
hormone disregulation74 and not surprisingly, disease states associated with ketosis may
have varying degrees of hepatic lipidosis. Any of the aforementioned PRMDs may also occur
with concurrent mastitis, metritis, retained placenta, or other health problems, begging the
question as to whether or not affected animals may have a genetic predisposition for this
problem. Since PRMDs are not limited to a single phenotype, and represent an array of
disorders having inter-related causes, including dietary and environmental management
practices, biomarkers that can identify the downstream responses to production demands in
dairy cows associated with these metabolic disorders would be a valuable tool to detect the
animals at risk, thereby allowing for appropriate interventions.

Lipid metabolism has been found to be abnormal in certain metabolic diseases in dairy
cows75. For example, the liver triglyceride to glycogen ratio has been used to predict
susceptibility of cows to ketosis.75 Increase in plasma non-esterified fatty acids (NEFA) and
β-hydroxybutyrate (BHBA) are both significantly associated with development of peripartum
diseases.42 Milk fatty acids, such as C18:1 cis-9, have been proposed as possible biomarkers
able to diagnose elevated concentrations of plasma NEFA early in dairy cows.76 However,
there has not been a comprehensive study of lipid biomarkers with the intent of their
anticipating PRMDs. Most current research has focused on dietary management and how
diet and/or environmental interactions (e.g., over-conditioning at calving, low nutrient
intake, environmental stress) can lead to peripartum diseases. Therefore, it is still highly
desirable to discover novel biomarkers that are able to predict PRMDs with adequate

32

sensitivity and specificity.

In other previous studies, lipids have been shown to be related to metabolic disorders,
including ketosis77and fatty liver 78 which are also associated with development of DA and
milk fever. The majority of PRMDs occurs after calving,

during early lactation, and are

believed to be due to difficulty adapting to the high demands of lactation, resulting in
physiological imbalances in susceptible cows.79 Since colostrum and milk are both rich in
lipids, and readily accessible for collection, we hypothesized that lipid expression differences
in colostrum and milk samples between PRMD susceptible and resistant dairy cows would
exist and could be potential predictive biomarkers.

‘Shotgun’, i.e., in-depth or comprehensive, lipidomics can survey thousands of unique lipids
in a single biological specimen. One such lipidomic approach using direct injection,
electrospray ionization coupled with highly mass accurate, tandem-mass spectrometers
(ESI/MS/MS) represents a powerful tool for cataloguing, quantifying and chemically
characterizing lipids20 in tissue, cell or body fluids. Lipidomics can complement peptidomic
and proteomic methods. Indeed, colostrum and milk samples can be readily fractionated
into lipid- and protein-rich layers. Lipidomics, especially direct injection lipidomics, is
substantially less involved than top-down, global proteomic methods, which typically require
enzyme digestion and multiple separation steps prior to MS. Consequently, lipidomics is well
suited for the discovery of lipid biomarkers. Early, predictive biomarkers could help detect a
cow’s propensity for PRMDs in advance, to allow for prevention or early stage treatment
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interventions. Susceptible cows could be treated with extra nutrients, minerals, or other
supplements, along with a health-promoting environment, to reduce animal losses80 while
maintaining a physiologically compatible, albeit lower level of milk production. PRMD
susceptible cows could be later reintroduced to the herd after their health was stable, and
lactation parameters met economic production criteria.

3.3 Materials and lipid standards
Reproducibility and quantitative comparisons using direct injection lipidomics are
dramatically improved with the introduction of known, consistent amounts of one or more
synthetic lipid standards to the specimen to be analyzed. The synthetic lipid standard used in
these studies was archeol (2, 3-diphytanyl-sn-glycerol), purchased from Avanti Polar Lipids,
Inc. (Alabaser, AL, USA). Chloroform (HPLC grade) was purchased from Avantor Performance
Materials, Inc. (Center Valley, PA, USA). Methanol (Optima LC/MS) was purchased from
Fisher Scientific (Fair Lawn, NJ, USA). Isopropyl alcohol (suitable for LC and
UV-spectrophotometry) and ammonium acetate were purchased from Mallinckrodt
Chemicals, Inc. (Phillipsburg, NJ, USA)

3.4 Sample collection and analysis
Sample collection:
Randomly chosen, age-, lactation-, and parity-matched clinically normal primiparous (n =
101) and multiparous (n=109) Holstein cows at Brigham Creek Dairy (Elberta, UT) were
studied. Cows received the same dry cow total mixed ration prepartum and were fed the
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same fresh cow, early lactation diet the first week postpartum.

Composite aliquots of colostrum secreted on the day of parturition and milk produced on
the fourth day of lactation were collected from the four quarters of each cow’s udder as it
pooled in a milking claw and was sampled via the exit milk tube. Samples were collected in
50 mL conical vials, then buried immediately and completely in crushed ice for transport
from Brigham Creek Dairy, Elberta, UT, to the lab at Brigham Young University, Provo, UT.
Each sample was divided into 10 mL aliquots before being flash frozen in liquid N2 in a Dewar
flask and stored in a -80oC freezer until later analysis.

Animal health records were monitored through 60 days in milk (DIM) for evidence of PRMDs
or other complication. The specific phenotypes considered were ketosis, left displacement
abomasum (LDA), milk fever (MF), fatty liver, and/or hind limb weakness attributed to
obturator nerve paresis (OP) (Table 3).

Lipid extraction:
Colostrum and milk samples were processed for lipidomic analysis in the same way. Selected
samples were taken from the -80oC freezer and thawed completely at room temperature.
Lipid and the aqueous protein fractions of colostrum (or milk) were separated by
centrifugation (Sorvall Legend XTR Centrifuge, Thermo Scientific) for 20 min at 650 x g at 4oC.
After separation, 10 mg of the upper, lipid containing layer of the sample was taken and
dissolved in 3.8 mL of a 2:1:1.25 (v/v/v) solution of chloroform:methanol:isopropanol81.
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After shaking the mixture for 30 s until complete lipid dissolution, 1.2 mL of double distilled
deionized water was added and the mixture was shaken vigorously and then allowed to sit
for organic and aqueous layer separation. After incubating at 37oC overnight for complete
lipid extraction, the bottom organic phase was taken and diluted 500 times with a 2:1:1.25
(v/v/v) solution of chloroform:methanol:isopropanol containing 15 mM of ammonium
acetate and containing the lipid standard archaeol (6 nM) just prior to instrumental analysis.

Lipid profiling by time-of-flight mass spectrometry:
Mass spectrometric analysis was performed on an electrospray ionization source
time-of-flight mass spectrometer (6230 ESI-TOFMS, Agilent Technologies). The ionization
voltage was set to 3.5 kV, gas pressure to 15 psi and the source was controlled by Agilent
MassHunter Workstation Data Acquisition software (Agilent Technologies, Santa Clara, CA,
USA). All lipid samples were infused at the flow rate of 10 µL/min by a syringe pump (New
Era Pump Systems, Inc, Farmingdale, NY, USA) and analyzed in positive ion mode for 3 min
with MS data collected over the range from m/z 100 to 1500. Technical replicates (n = 2)
were performed for each sample and the values averaged in order to minimize instrumental
variability.

Data analysis:
Instrument software (Agilent MassHunter Qualitative Analysis B.07.00 software, Agilent
Technologies, Santa Clara, CA, USA) was used to generate a peak list with the abundance of
each lipid (ion counts) recorded for each specimen. The abundances of the 2 instrumental
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replicates were exported as CSV files using Agilent MassHunter. Two columns are generated
in each file, including a peak list with m/z values and the corresponding abundances. The
peaks were aligned between each run by a home-made macro program within an Excel file
through Visual Basic Programming Language according to the m/z values and the associated
abundances recorded. Accuracy of peak alignment by mass between samples was further
checked manually. The intensity of the lipid standard in each run was determined and used
for data normalization. Then, the normalized abundances of the 2 instrumental replicates
were averaged.

Statistical analysis:
In order to find useful biomarkers that distinguish PRMD-resistant and susceptible animals,
an initial, two-tailed Student’s t-test was carried out on the normalized abundances for the
two comparison groups. Those lipid molecules having a p-value less than 0.05 were
compiled and submitted for further discriminant statistical analysis. Colostrum and milk
samples were analyzed separately. Furthermore, the ‘shared’ significant m/z values between
colostrum and milk, i.e., those species that were significantly different in both milk and
colostrum, were selected, and the differences between the normalized abundances for each
peak were calculated by subtraction, and the differences further considered in the statistical
analyses.

Lipid compounds found in significantly different, quantitative abundances based on the
Student t-test, were included in a second data set that was submitted to linear
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discriminative analysis to model combinations or panels of milk and/or colostrum
biomarkers (SAS 9.3, SAS Institute Inc., Cary, NC, USA). Linear discriminant analysis has been
described previously42. In brief, each statistically different lipid was evaluated in a step-wise
discriminant statistical analysis with it being the independent variable of lipid abundance in
samples and HSC ranking (heath score): 0 (healthy) or 1 (PRMD treated/culled/died within 2
months postpartum) being the dependent variables. A significance level of p <0.05 was
considered significant for all tests. Discriminant analysis, grouping variable HSC, was
performed for each colostrum (CS) and milk (MK) measure. Calculated differences between
‘shared’ markers were obtained through significant m/z values of normalized abundance of
colostrum minus normalized abundance of milk. A two-sample t-test was carried out to
determine significant differences in the measurable abundance of lipid species found in
colostrum and milk. Further statistical analysis was performed using a general linear model
procedure (PROC GLM) with SAS (version 9.3) to determine differences between PRMD
positive and negative cows’ lipid species found in colostrum, milk, or shared in both
substrates.

Additionally, after reviewing the results in milk, it was observed that all lipid biomarkers of a
particular m/z range were increased in milk of animals later developing PRMDs whereas all
the lipid biomarkers in a higher m/z range were reduced in disease susceptible animals. To
test the significance of this, a 2x2 contingency table was created that looked at the
classification of diseased animals with the consistency of an elevated or decreased
abundance observed for lipid biomarkers based on their m/z category. A Fisher Exact test
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was performed and a p-value <0.05 was considered significant.

Lipid identification:
Three panels of high performing predictive biomarkers were generated by statistical analysis.
Each marker in the three panels was then chemically characterized by ESI-tandem mass
spectrometry (MS/MS). Targeted MS/MS was applied to extracts in an effort to identify or
substantially characterize each useful biomarker. A combination of ‘exact’ mass studies,
together with MS/MS fragmentation studies using collisionally-induced dissociation, were
used to chemically characterize candidate biomarkers. Fragmentation data was acquired on
both a QSTAR Pulsar I quadrupole orthogonal time-of–flight mass spectrometer through an
IonSpray Source (Applied Biosystems, Foster City, CA, USA) and on an Agilent 6530
accurate-mass quadrupole/time-of flight mass spectrometry (Agilent Technologies, Santa
Clara, CA, USA). Specific colostrum and milk samples were selected for characterization
based on a higher abundance of the targeted lipid peak of interest being present and the
sample was extracted using 2:1:1.25 chloroform:methanol:isopropanol with 15 mM
ammonium acetate present.

One MS instrument, the QSTAR, had the following settings: voltage potential of 4800 V for
the ion spray needle coupled with a flow rate of 4 µL/min using the syringe pump. The
drying gas used was N2 and the collision gas was nitrogen. Optimal collision energies varied
depending on the size, structure, and abundance of the lipids, but were typically between 15
and 40 eV. Analyst QS software was used for controlling the instrument, and a 50 - 2000
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mass/charge range was used for each scan.

For the second instrument, the Agilent Q-TOF, direct infusion with the syringe pump was
used for sample injection at a flow rate of 10 µL/min. The ion selection quadrupole Q1 was
operated under the unit resolution settings, and fragments were detected within the m/z
range of 100 - 1000 using positive ion mode. Each MS/MS spectrum was acquired for 30 s
with a collision energy range of 15 - 40 eV. An isolation window of 1.3 was used.

Chromatograms were extracted from ESI total ion chromatograph (TIC) at a MS/MS level
with Agilent MassHunter Qualitative Analysis B.07.00 (Agilent Technologies, Santa Clara, CA,
USA). The exported product ion mode was broadly used for lipids identification. Predicted
identities of target lipids were searched for using the on-line reference site LIPID MAPS82 and
the Elemental Composition Calculator programed by Frank Antolasic was used in
conjunction with the experimentally determined accurate mass of lipids after determination
of their detected adduct. Fragmentation information was further manually determined in
product ion mode through review of neutral loss species, or scanned fragment information.
The LIPID MAPS MS fragment prediction tool (http://www.lipidmaps.org/tools/index.html)
was also applied to determine the product ion peak lists, which often represented sn1 and
sn2 acyl losses mainly for glycerolipids.

3.5 Results
Descriptive Data:
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Day 1 colostrum and day 4 milk secretions were collected from 101 primiparous and 109
multiparous asymptomatic postpartum Holstein cows. Approximately 10% of the cows from
this larger cohort developed PRMDs within 24 weeks after calving. Therefore, their samples
were selected along with healthy matched controls, and submitted to lipidomic analysis. The
‘disease’ cows were diagnosed with PRMDs, that included abnormalities such as ketosis, left
displaced abomasum (LDA), hypocalcemia (commonly known as milk fever (MF)) and
obturator nerve paresis (OP) as shown in Table 3. All cows enrolled in the study were
monitored for the development of PRMDs and their health history records were tracked for
8 weeks postpartum in order to select healthy control and PRMD samples for this study.
Controls were matched by age, parity, and lactation to animals that developed PRMDs and
sorted according to similar date of calving. The selected samples are described in the
demographics table (Table 3) that includes cow ID number, the diagnosis group (disease or
control), and phenotype. Cow 19010, 21389 and 23567 did not have milk collected on day 4
after calving due to illness or no longer being in the herd. Cow 23608 and 23971 did not
have milk samples due to specimen loss or it being compromised. Cow 23374 was diagnosed
with suspected milk fever, but was not included in the final data analysis due to uncertainty
of the health record diagnosis.

Significant lipid biomolecules between PRMD resistant and susceptible cows through lipids
profiling approach:
A peak list of m/z values, i.e., a list of lipid species observed in the MS, with their
corresponding abundances (ion counts > 600) were exported from the Qq-TOF mass
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spectrometer using Agilent MassHunter Qualitative Analysis B.07.00 software (Agilent
Technologies, Santa Clara, CA, USA). A total of 1800-2000 ion peaks (ion counts > 600),
representing potentially that number of different lipids, were detected in MS runs of
separately analyzed colostrum and milk samples. After peak alignment among all the
colostrum or milk samples based on the m/z, normalization was carried out by using the
ratio of the peak abundance to the abundance of the internal standard. A Student’s t-test
was applied within Excel for both colostrum and milk lipids. Some potential markers with
statistically significant differences (p-value <0.05) between diseases and controls are listed in
Table 3 and Table 4. In total, 61 statistically significant, quantitatively different lipids were
discovered in colostrum (Table 3), and 77 significant, quantitatively different lipids were
discovered in milk (Table 4). Of these, 31 lipids were found to be significantly different
between cases and controls in both colostrum and milk. Additionally, for these ‘shared’
markers, differences between colostrum and milk values of the same peak were calculated
by using normalized abundances of that lipid in colostrum minus its normalized abundance
in milk. P-values of shared differences were calculated with SAS 9.3 as provided in Table 5.
Further statistical modeling suggested how predictive these markers are for PRMD resistant
and susceptible dairy cows as shown in Figure 11.
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D or C

Cow ID

Diagnosis

Lipids

C

19048

-

csmk

C

20505

-

csmk

C

20804

-

csmk

C

20873

-

csmk

C

21132

-

csmk

C

21155

-

cs

C

21247

-

csmk

C

21859

-

csmk

C

22219

-

csmk

C

22598

-

csmk

C

22877

-

csmk

C

23609

-

csmk

C

23772

-

csmk

C

26556

-

csmk

C

26558

C

26678

-

csmk

C

26776

-

csmk

C

26852

-

csmk

C

26998

-

csmk

C

29241

-

csmk

C

29552

-

csmk

C

29554

-

cs

C

29610

-

cs

D

14112

Died

csmk

D

16320

MF

csmk

D

17829

OP, Died

csmk

D

17841

MF, Died

csmk

D

19010

MF

cs

D

20594

LDA

csmk

D

20712

LDA

csmk

D

21389

LDA

csmk

D

22377

LDA

csmk

D

23567

MF, LDA

cs

D

23608

LDA

cs

D

23762

LDA

csmk

D

23971

LDA

cs

D

25249

LDA

csmk

D

25853

LDA

csmk

D

26035

MF, OP

csmk

D

26832

LDA

csmk

D

29337

LDA

csmk

D

29551

LDA

csmk

csmk
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D

29685

LDA

csmk

SuspD

23374

SuspectMF

Csmk

Table 3. Demographics. Postpartum first day colostrum and milk secreted on day 4 were collected from 210
Holstein cows; cows that developed PRMDs were selected as diseased animals and compared with age, parity,
and lactation matched controls. D: disease; C: control; MF: hypocalcemia, commonly known as milk fever; LDA:
left displaced abomasum; OP: obturator nerve paresis; CS: colostrum; MK: milk
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Candidate No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

m/z value
344.2247
388.2525
489.1043
570.4639
586.5356
598.5014
612.5527
615.5605
648.463
652.5473
654.5636
659.5223
668.5827
675.4999
680.5771
682.5948
687.5507
694.5999
695.5915
696.6045
703.5253
704.5477
706.587
708.6098
710.6251
723.6208
731.5633
732.5673
734.6126
736.6403
749.6357
751.6513
752.6595
848.7654
850.7813
855.7364
858.7473
861.574
862.788
864.788
872.745
873.7445
874.7789
876.7964
878.8096
881.7594
883.759
889.7908
890.8055
891.8077
897.7294
899.7562
900.7894
902.8102
904.8244
906.8353
917.8214
919.8341
964.5856
965.6969
967.7134

normalized value of diseases
0.114880157
0.121962693
0.373807522
0.176409178
0.202742707
0.112665915
0.065970917
0.069239485
0.085478463
0.09833478
0.939107997
0.198002601
0.16539349
0.126403559
0.513222007
2.590566861
0.380657952
0.107000465
0.19157094
0.225131134
0.262044497
0.134370476
0.217696672
0.732302369
1.197685611
0.399721453
0.12838516
0.113258213
0.098106733
0.249638522
0.126106942
0.196540202
0.139024989
0.934633969
2.586551283
0.491215538
0.101043456
0.070961192
0.166454098
0.32486829
0.222708437
0.154204103
0.477500575
1.366009113
0.961036568
0.304220425
0.201953914
0.142787896
0.151286664
0.338952477
0.157819943
0.139790521
0.220946001
0.365998427
0.333156789
0.180777646
0.169726223
0.123850821
0.073206947
0.107055016
0.122811632

normalized value of controls Abundance comparison
0.103689575
Higher in dieases
0.112940105
Higher in dieases
0.290967829
Higher in dieases
0.11189889
Higher in dieases
0.265637153
Higher in controls
0.080800463
Higher in diseases
0.078148394
Higher in controls
0.087939768
Higher in controls
0.115099741
Higher in controls
0.07354011
Higher in diseases
0.652840941
Higher in diseases
0.142805881
Higher in diseases
0.11621013
Higher in diseases
0.099737468
Higher in diseases
0.349466169
Higher in diseases
1.404894949
Higher in diseases
0.224279411
Higher in diseases
0.067609268
Higher in diseases
0.138180817
Higher in diseases
0.148052417
Higher in diseases
0.163091281
Higher in diseases
0.081080697
Higher in diseases
0.140102698
Higher in diseases
0.366041823
Higher in diseases
0.752962244
Higher in diseases
0.242845266
Higher in diseases
0.084643368
Higher in diseases
0.082269331
Higher in diseases
0.07821988
Higher in diseases
0.1680125
Higher in diseases
0.068235491
Higher in diseases
0.133759701
Higher in diseases
0.105137977
Higher in diseases
0.749696345
Higher in diseases
2.001595098
Higher in diseases
0.395923832
Higher in diseases
0.074631085
Higher in diseases
0.099041479
Higher in controls
0.11855104
Higher in diseases
0.263356503
Higher in diseases
0.18695274
Higher in diseases
0.12767435
Higher in diseases
0.329773294
Higher in diseases
0.692794525
Higher in diseases
0.493672525
Higher in diseases
0.175428923
Higher in diseases
0.112400998
Higher in diseases
0.118691043
Higher in diseases
0.110704439
Higher in diseases
0.272686318
Higher in diseases
0.098184814
Higher in diseases
0.08871563
Higher in diseases
0.139311432
Higher in diseases
0.175549359
Higher in diseases
0.156091233
Higher in diseases
0.101178543
Higher in diseases
0.098529751
Higher in diseases
0.066611016
Higher in diseases
0.105163006
Higher in controls
0.06447254
Higher in diseases
0.10158746
Higher in diseases

p value
0.042061688
0.048555005
0.049572488
0.013504484
0.001414111
0.028964416
0.043833247
0.042757696
0.049597223
0.04724037
0.014671469
0.004243638
0.015227126
0.034354145
0.004172134
0.000949216
0.000405532
0.003174857
0.007715938
0.002541267
0.001391699
0.000546421
0.002698514
0.000466794
0.002817283
0.001139869
0.001933664
0.005490254
0.039988195
0.003092746
0.000335962
0.002955134
0.011054544
0.01734462
0.007887614
0.006170212
0.000650882
0.035043823
0.00492844
0.007491634
0.023286159
0.016994617
0.000405247
0.00025238
0.000466523
6.91957E-05
0.000112302
0.015486554
0.0015826
0.007426845
0.00036568
0.000225419
0.000267302
0.000451383
0.00073496
0.000967386
0.000225545
0.000146124
0.015808127
0.000659915
0.036742958

Table 4. Significant PRMD predictive lipid biomarkers (p<0.05) in colostrum. P values were obtained by
Student’s t-test between PRMD susceptible and resistant dairy cows. The means of normalized abundance in
20 diseased animals and 22 controls are shown in the 3rd and 4th columns.
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Candidate No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77

disease
572.4828
600.5146
626.5314
628.5465
633.5
640.5417
642.5606
652.5463
654.5626
656.5783
657.5816
658.5805
659.5156
661.5323
668.5788
669.5772
670.5907
675.4994
677.507
684.6074
689.5597
695.5945
697.6055
705.5422
712.6371
717.583
721.5006
725.6337
732.5781
733.5725
734.6183
738.6543
740.6681
752.6554
753.6635
754.6695
764.6702
766.6855
768.6997
780.6912
792.7012
794.7174
808.7291
809.7327
810.7431
848.7645
850.7802
855.7365
862.7773
863.7788
864.7913
865.7945
872.7541
874.7794
876.7962
878.8092
879.8124
881.7614
883.7632
888.789
889.7915
890.8051
891.8074
896.7527
897.7299
898.76
900.7909
902.8106
904.8246
906.836
908.8049
909.7825
915.8031
917.8208
919.8333
939.6842
967.7069

disease _mean
0.227073934
0.426188238
0.332706621
1.404315699
0.150864782
0.105486833
0.270175612
0.163679734
1.572666631
4.802102104
1.821030483
0.415087477
0.270610645
0.450185483
0.314661478
0.310755852
0.530011614
0.142120983
0.295841154
4.038547322
0.404386212
0.288641146
0.762463331
0.280096199
1.282073361
0.154938615
0.193633957
0.552109984
0.132098686
0.117869841
0.116226648
0.744455276
0.493078794
0.229681858
0.1902872
0.123341686
0.234524451
0.478029349
0.396400708
0.094034212
0.221344994
0.537540377
0.111769356
0.095715993
0.111801112
1.205927939
3.14024801
0.458887525
0.261855371
0.262347251
0.444669242
0.287828953
0.240567243
0.884013552
3.975003341
2.900494826
1.398439996
0.612866418
0.430026039
0.123029972
0.192554315
0.317900205
0.453012105
0.090403386
0.303077206
0.232897889
0.393967161
1.199197503
1.308415831
0.588400876
0.157094249
0.221899985
0.107663063
0.374602543
0.29246751
0.188264489
0.16795484

control_mean
0.489156442
0.918376635
0.530873278
2.637108898
0.265523759
0.135917624
0.451766164
0.21762311
2.098405246
6.779852288
2.549534246
0.561397172
0.332875614
0.620125673
0.390475848
0.47647484
0.733158168
0.197464108
0.439742727
5.375889332
0.525474832
0.348551776
0.974135232
0.389001747
1.879963512
0.219021411
0.23423158
0.70004443
0.16261439
0.172986401
0.156062153
1.048604892
0.834138952
0.274217616
0.265708582
0.185374768
0.302551159
0.723050046
0.590469763
0.132513766
0.282647947
0.700470268
0.145186647
0.126344779
0.139741421
0.97061175
2.310057231
0.352796522
0.206431713
0.229356579
0.343999739
0.231822591
0.203867439
0.601752056
2.283182118
1.794288368
0.894483247
0.381728559
0.285768862
0.086810486
0.14362613
0.212723122
0.312917793
0.075289411
0.222820825
0.176361653
0.269274785
0.637454941
0.719666079
0.365295263
0.110560115
0.133238648
0.075385692
0.223599465
0.187698404
0.240903499
0.19725702

Abundance comparison
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in controls
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in diseases
Higher in controls
Higher in controls

p value
5.66205E-05
1.72877E-05
0.000134814
4.38457E-06
9.266E-06
0.005901871
2.83684E-07
0.001433185
0.000953975
2.41044E-05
2.62771E-05
4.48915E-05
0.005245116
3.67155E-05
0.003101227
1.96141E-06
1.14043E-05
0.00216583
0.002393067
0.000453034
0.000420062
0.010188417
0.000186872
0.008195311
5.97024E-05
8.00007E-05
0.048132457
0.001084341
0.027660775
0.002006596
0.000653951
0.000161202
0.000370689
0.007499157
5.5045E-05
1.45157E-05
0.000746323
0.000156398
0.020185394
2.56998E-05
0.001632091
0.01869102
0.000464602
0.01393217
0.028215881
0.001509529
2.60282E-05
6.91148E-06
0.003570806
0.005640039
0.000307567
0.000241857
0.02493066
0.000311042
4.45627E-05
2.01532E-05
2.12595E-05
5.98877E-06
7.37893E-06
0.000846913
0.000244128
0.000149677
1.28318E-05
0.022673036
0.012642883
0.006328352
0.000288913
2.18259E-05
1.31168E-05
1.85972E-05
8.6087E-05
5.60766E-06
0.000332921
5.61349E-05
4.94772E-05
0.000158301
0.005952086

Table 5. Significant PRMD predictive lipid biomarkers (p <0.05) in milk. P-values were obtained by Student’s
t-test between PRMD susceptible and resistant dairy cows. The means of the normalized abundance in 16
diseased animals and 20 controls are shown in the 3rd and 4th columns.
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Obs biomolecules

Mean_C

Mean_D Difference

StdErr

DF

tValue Probt

0.01650

34

-4.92 <.0001

1

DF652_5473

-0.1448 -0.06356 -0.08124

2

DF654_5636

-1.4531 -0.6123

-0.8407

0.1475

34

-5.70 <.0001

3

DF659_5223

-0.1912 -0.06697

-0.1243

0.02416

34

-5.14 <.0001

4

DF668_5827

-0.2751 -0.1447

-0.1304

0.02803

34

-4.65 <.0001

5

DF675_4999 -0.09726 -0.01074 -0.08652

0.02147

34

-4.03 0.0003

6

DF695_5915

-0.1217

0.02325

34

-5.23 <.0001

7

DF732_5673 -0.07994 -0.01389 -0.06605

-0.2121 -0.09033

0.01811

34

-3.65 0.0009

8

DF734_6126 -0.07823 -0.01643 -0.06180

0.01415

34

-4.37 0.0001

9

DF752_6595

-0.1702 -0.08774 -0.08243

0.01767

34

-4.67 <.0001

10

DF848_7654

-0.2434 -0.2847

0.04131

0.09265

34

0.4 0.6585

11

DF850_7813

-0.3721 -0.5994

0.2273

0.2663

34

0.85 0.3993

12

DF855_7364

0.03917 0.02702

0.01215

0.04909

13

DF862_788

-0.09118 -0.09356 0.002384

0.02681

34

0.09 0.9297

14

DF864_788

-0.08544 -0.1160

0.03793

34

0.81 0.4263

15

DF872_745

-0.01984 -0.01910 -0.00074

16

DF874_7789

-0.2784 -0.4047

0.1263

0.07273

34

1.74 0.0915

17

DF876_7964

-1.6041 -2.5649

0.9608

0.3163

34

3.04 0.0046

18

DF878_8096

-1.3085 -1.8992

0.5907

0.2005

34

2.95 0.0058

19

DF881_7594

-0.2066 -0.2989

0.09229

0.04264

34

2.16 0.0375

20

DF883_759

-0.1734 -0.2197

0.04625

0.03018

34

1.53 0.1346

21

DF889_7908 -0.02712 -0.04889

0.02177

0.01526

34

1.43 0.1629

22

DF890_8055

-0.1029 -0.1628

0.05986

0.02474

34

2.42 0.0210

23

DF891_8077 -0.04577 -0.1122

0.06643

0.03648

34

1.82 0.0774

24

DF897_7294

-0.1247 -0.1399

0.01526

0.03527

34

0.43 0.6680

25

DF900_7894

-0.1311 -0.1644

0.03338

0.03462

34

0.96 0.3417

0.03054

0.02608

34

34

0.25 0.8059

-0.03 0.9777

26

DF902_8102

-0.4627 -0.8160

0.3533

0.09900

34

3.57 0.0011

27

DF904_8244

-0.5646 -0.9608

0.3962

0.09890

34

4.01 0.0003

28

DF906_8353

-0.2650 -0.4005

0.1355

0.03998

34

3.39 0.0018

29

DF917_8214

-0.1262 -0.1980

0.07175

0.02924

34

2.45 0.0194

30

DF919_8341

-0.1202 -0.1625

0.04225

0.02184

34

1.93 0.0614

31

DF967_7134 -0.09657 -0.04388 -0.05269

0.01299

34

-4.06 0.0003

Table 6. Statistical analysis of ‘shared’ peak differences, i.e. for lipids significantly different between diseased
and control animals in both colostrum and milk. The differences of shared biomarkers were calculated by using
the normalized abundance of colostrum minus the normalized abundance of milk. Mean_C: mean differences
of controls; Mean_D: mean differences of diseases; 31 shared peaks were found as shown, p values named as
Probt in the rightmost column were obtained through SAS 9.3.
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Figure 7. Representative mass spectra of PRMDs lipid marker at m/z 682.59 from 6 colostrum samples. The
peak at 670.70 m/z is the ammoniated internal standard archaeol. The upper three samples are diseased cows
(14112, 17841, 20712), and the bottom three are control cows (20873, 22219, 21859). Reproducible internal
standard was shown in randomized MS runs. As observed in these 6 colostrum samples’ mass spectra, m/z
682.59 is more highly expressed in cows which later developed PRMDs compared to control animals that
remained healthy.
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Statistical modeling of predictive PRMD lipid biomarker panels:
The best colostrum biomarker panel as found for these data using linear discriminative
analysis contained three lipids as shown in Figure 8. The panel yielded 90.0% sensitivity and
86.4% specificity. The best milk biomarker panel contained two lipids as shown in Figure 9,
which provided a sensitivity of 75.0 % at a specificity of 90.0%. In addition, an optimized
combined colostrum and milk biomarker panel included 7 lipid markers: 2 lipids were from
the colostrum data set, 2 lipids were from the milk data set, and 3 markers represented
calculated differences between colostrum and milk for the ‘shared’ marker set. The
combined biomarker panel yielded 87.5% sensitivity and 100.0% specificity (Figure 10).
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(a)

50

Normalized Abundance

0.6
0.5
0.4
0.3
0.2
0.1
0

570_disease

570_control

Marker m/z 570.46

(b)

51

Normalized Abundance

0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0

586_disease

586_control

Marker m/z 586.53

(c)

52

1
0.9

Normalized Abundance

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

855_disease
855_control
Marker m/z 855.74

(d)
Figure 8. (a) Comparison of the panel of 3 colostrum lipid markers at m/z 570.4639, 586.5356 and 855.7473 of
PRMD susceptible (n = 20) and PRMD resistant (n = 22) cows. SE: standard error (b) Boxplot of colostrum
marker m/z 570.46. (c) Boxplot of colostrum marker m/z 586.53. (d) Boxplot of colostrum marker m/z 855.74.
The y-axis is the normalized abundance. The boxplot data were from 20 cows that developed PRMDs and 22
healthy controls.
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Figure 9. (a) Comparison of the 2 milk lipid markers at m/z 642.5606 and 906.836 yielding the optimum panel
of PRMD susceptible (n = 16) and PRMD resistant (n = 20) cows. (b) Boxplot of milk marker m/z 642.56. (c)
Boxplot of milk marker m/z 906.83. The y-axis represents normalized abundance. Boxplot was obtained from
16 cows that developed PRMDs and 20 healthy controls.
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Figure 10. (a) Representation of a panel of 7 predictive PRMD lipid biomarkers. MK: milk; CS: colostrum; DF:
difference for shared markers; DF = normalized abundance of CS – normalized abundance of MK; Milk lipids
m/z 642.5606 and 740.6681 and colostrum lipids m/z 344.2247 and 682.5948 were selected for the panel.
Additionally, three calculated differences for shared markers (different in both colostrum and milk) with
statistical differences between animals that later developed PRMDs and cases were included. Lipids with m/z
652.5473, 906.8353 and 919.8341 shown as negative mean values indicated the normalized abundance of the
biomarker in milk was higher than in colostrum. (b) Boxplot of milk lipid m/z 642.56. (c) Boxplot of milk lipid
m/z 740.66. (d) Boxplot of colostrum lipid m/z 344.22. (e) Boxplot of colostrum lipid m/z 682.59. (f) Boxplot of
normalized shifted abundance differences of colostrum and milk marker m/z 652.54. Y-axis (normalized DF
abundance) was shifted by 0.2615. (g) Boxplot of normalized abundance differences of colostrum and milk
marker m/z 906.83. Y-axis was shifted by 0.5821. (h) Boxplot of normalized abundance differences of colostrum
and milk marker m/z 919.83. Y-axis of normalized DF abundance was shifted by 0.3208.

Characterization of PRMD biomarker candidates:
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Lipid marker structures were identified by means of targeted MS/MS analyses on the QSTAR
and/or QqTOF using collisionally-induced dissociation (CID). The markers that made up the
three panels were submitted to this further characterization. This represented 10 unique
lipid biomarkers that needed to be chemically characterized. Of these, 5 markers were
successfully identified as triacylglycerols (TG), including m/z 855.7473 which represented the
protonated TG (16:0/18:1/18:3) determined based on 2 abundant fragments at m/z 573.49
and m/z 599.48. The marker m/z 906.836 was first determined to be an ammoniated TG
because of a peak at [M+NH4 -17]+. Utilizing this same approach, marker m/z 740.6681 was
characterized as [TG (12:0/14:0/16:0)+NH4]+. Identification studies on the marker m/z
919.8341 yielded two possibilities, including an oxidized TG (18:0/18:0/19:1)+OH+ or an
oxidized TG (18:0/18:1/19:0)+OH+. As for the marker m/z 682.5948, a NH3 neutral loss was
observed in the spectra. And the exact mass of marker m/z 664.56 suggested its elemental
composition to be C41H76O6, which indicates strongly that the marker is a TG. Three of the 10
markers were categorized as diacylglycerols (DG) through the same approach with
determinations based on the fragments and neutral losses in the fragmentation spectra. The
fragmentation studies identified these 3 markers to be DG (16:0/16:0), DG (18:0/18:0) and
DG (18:2/19:0).

The elemental composition of the last two lipid markers m/z 570.4639 and m/z 344.2247
were determined as [C40H56O+NH4]+ and [C21H26O3+NH4]+. However, these two markers were
not classified into a specific lipid group due to lack of identifiable headgroups or
recognizable constituent species in the fragmentation data.
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Predictors

Elemental
composition

Identification

Abundance

P Value
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570.4639

C40H56O+NH4

NA

586.5356

C35H68O5+NH4

DG(16:0/16:0)

855.7473

C55H98O6+H

TG(16:0/18:1/18:3)

Higher in
diseases
Higher in
controls
Higher in
Diseases

0.013504484
0.001414111

0.000650882

Table 7. Identification of predictive PRMD lipid markers that were part of the optimized
panel for colostrum. These provided 90.0% sensitivity at 86.4% specificity. This panel
predicted 19 out of 22 control cows and 18 out of 20 cows with later PRMDs.

Predictors

Elemental
composition

Identification

Abundance

P Value
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642.5606

C39H76O5+NH4

DG(18:0/18:0)

906.836

C57H108O6
+NH4

TG(18:0/18:0/18:1)

Higher in
controls
Higher in
diseases

2.83684E-07
1.85972E-05

Table 8. Characterization of predictive PRMD milk biomarkers. An optimized predictor panel
of milk lipids provided 75.0% sensitivity at 90.0% specificity, by predicting 12 out of 16 cows
that later developed PRMDs and 18 out of 20 cows that remained healthy that were used as
controls.

Predictors

Elemental

Identification

Abundance P Value
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composition
MK642.5606 C39H76O5+NH4

DG(18:0/18:0)

Higher in
2.83684E-07
controls
CS682.5948 C41H76O6+NH4
TG
Higher in
0.000949216
diseases
CS344.2247 C21H26O3+NH4
NA
Higher in
0.042061688
diseases
DF906.8353 C57H108O6 +NH4
TG(18:0/18:0/18:1)
Higher
0.0614
changes in
diseases
DF919.8341 C58H110O6+OH
TG
Higher
0.0018
(18:0/18:0/19:1)+OH; changes in
TG
diseases
(18:0/18:1/19:0)+OH
DF652.5473 C40H74O5+NH4
DG(18:2/19:0)
Higher
<.0001
changes in
controls
MK740.6681 C45H86O6+NH4
TG(12:0/14:0/16:0)
Higher in
0.000370689
controls
Table 9. Characterization of predictive PRMD biomarkers combining colostrum, milk and
shared markers. An optimized predictor panel using a combination of colostrum, milk and
the differences between milk and colostrum for ‘shared’ lipids found in both of these
secretions showing significant differences in both colostrum and milk, provided 87.5%
sensitivity at a specificity of 100.0%, by predicting 14 out of 16 cows that later developed
PRMDs and 20 out of 20 cows that remained healthy and served as controls. The difference
(DF) between the normalized abundance of the biomarker for lipids with m/z 652.5473,
906.8353 and 919.8341 indicated it was higher in milk than in colostrum.

69

3.6 Discussion
Production-related metabolic diseases (PRMDs) have one of the highest incidences of
any disease in dairy cows worldwide, e.g., on average milk fever occurs in ~7% of all animals
after calving and displaced abomasum in ~5% of cows in well managed dairy herds, which
requires appropriate management and treatments that may include surgical intervention or
even loss of the animal depending on the severity of the disease at the time of diagnosis. A
condition like left displaced abomasum (LDA) can require increased costs for labor, drugs
and/or surgery, as well as reduced milk production, fertility issues, and possibly death of the
cow. Prevention of PRMDs is more efficient and much cheaper than any treatment for the
aforementioned diseases. Thus, a useful and easy way of predicting cows at risk for PRMDs
in advance of clinical signs is necessary and would be significant in helping preserve dairy
cow health to enhance overall herd production and to lower economic losses.
Previous attempts to predict cows at risk for PRMDs have focused on circulating levels of
lipids in blood plasma or serum. Animals with an elevated serum NEFA concentration (more
than 0.3 mEq/L) 14 to 2 days prior to calving or animals with an elevated serum BHBA
concentration (more than 10 mg/dL) and NEFA concentration (more than 0.6 mEq/L) 3 to 14
days postpartum, have been shown to be at an increased risk of transition diseases in dairy
cows (see Figure 2 for a summary of specificity and sensitivity using NEFA and BHBA as
predictors for transition diseases).42 However, the sensitivity and specificity of both of these
markers are inadequate to be useful, are labor intense to collect venipuncture derived
samples, and perform much less well than the biomarkers described here. We recognize that
more samples from geographically distinct regions are needed for analysis in order to
validate our results, to be confident that the observed biomarkers from our study are
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present in other cows from unrelated herds. The goal being to identify early, more efficient
and hence valuable lipid biomarkers in substrates that are readily available, easy to collect
such as colostrum or milk, and that are predictive of imminent PRMDs in asymptomatic
postpartum dairy cows.
A comprehensive lipidomics approach employing ESI-MS was for the first time applied
to lipid quantification and the selection of potential PRMD markers in day 1 postpartum
colostrum and day 4 postpartum milk. Here, 10 mg of the cream layer of colostrum or milk
was used for lipid extraction, and the resulting extract diluted 1000 times before loading the
specimen onto the ESI-MS. This dilution allowed most of the observed lipids to fall within
the linear dynamic concentration range of the instrument, i.e. the range over which ion
signal is directly proportional to the analyte concentration. Most of the lipids in colostrum or
milk are neutral lipids such as glycerolipids, and consequently a concentration of chloroform
twice that of methanol was used for the extraction step in order to obtain the broadest
representation of lipids in the organic phase. Statistical linear discriminative analysis was
then used to create different panels of biomarkers having greater predictive sensitivity and
specificity than individual markers. After developing optimal predictive biomarker panels,
targeted MS/MS analysis was performed to further chemically characterize the 10 relevant
lipid biomarkers obtained from statistical remodeling.
As shown in Table 4, among the 61 statistically significant biomarker candidates in
colostrum, 55 of them were present in higher concentration based on their normalized
abundances in dairy cows that subsequently developed PRMDs. The other 6 lipids were
present in higher levels in healthy controls. As previously demonstrated, a number of
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compounds, most notably IgG, nutrients (e.g., vitamins, lipids) and other serum proteins, are
secreted as colostrum accumulates in the mammary gland several weeks before calving
under the influence of various lactogenic hormones, including prolactin, 17β-estradiol,
insulin, etc83,84. The differences found in the aforementioned lipid biomarker candidates that
were secreted in colostrum and/or milk from cows that either developed PRMD or remained
healthy, may have occurred during the period prior to calving. Until now, there have been
few if any research studies carried out on day 1 colostrum as part of lipid biomarker
discovery.
There was a finding in the post-partum day 4 milk specimens, lipid biomarkers that
suggested a significant change in the biological composition of triglycerides in milk between
animals destined to develop PRMDs and those animals that remained healthy with normal
production status. Among the 77 statistically significant biomarker candidates in milk listed
in Table 5, those having m/z values from 572.48 to 810.74 (n = 45) were all higher in controls,
whereas those having m/z values from 848.76 to 919.83 (30 of 32) were higher in animals
that later developed disease. The remaining 2 statistically significant biomarker candidates
having m/z values of 939.68 and 967.71 were both higher in controls. Overall these lipid
‘class’ distinctions in milk were significant (p=2.3x10-19). All of these milk lipid biomarkers
appear to be triglycerides (TG). It has been previously established that the mammary gland
of the cow synthesizes de novo fatty acids with an even number of carbons of the 4:0-14:0
acids together with about half of the 16:0 from acetate and β-hydroxybutyrate that accounts
for approximately 60 and 45% of the fatty acids present in milk on a molar and weight basis,
respectively85. The remaining 40-60% of milk fatty acids are longer-chain 16:0 and
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predominantly C18 fatty acids derived mainly from dietary lipids, but are also from lipolysis of
adipose tissue triacylglycerols, which make their way into the circulation, mainly as plasma
NEFA and triglyceride-rich lipoproteins85. Thus, fatty acids incorporated into milk fat TGs are
provided either from mammary de novo synthesis or from the uptake of preformed fatty
acids from the peripheral circulation. Figure 3 illustrates the milk fat TG synthesis pathway.
Even though we did not determine the structure of all the milk lipid biomarkers, those lipids
with m/z values from 848.76 to 919.83 appear to represent longer chain TG based on their
m/z values and on the analysis of selected lipids in this range. Indeed, those milk biomarkers
that were included in the optimal panel, then fragmented and characterized having m/z
values of 906.83 and m/z 919.8341 were found to be TGs having longer chain fatty acid
components. These were higher in clinically normal cows that later developed PRMDs (see
Table 9). Milk lipids in the range of m/z 510 to ~810 are likely to be TGs composed of shorter
chain fatty acids. For example, the biomarker at m/z 740.668 was characterized as a TG
having shorter chain fatty acids present, i.e., 12:0/14:0/16:0 and was found in higher levels
in controls. Since the dairy cows that developed PRMDs and the matched control group
cows selected for this study were provided with the same feed, the differences in the lipid
biomarker concentrations between affected and healthy animals cannot be attributed to
diet.
The long chain fatty acid C18:1 cis-9 has been previously proposed as a possible
biomarker able to diagnose elevated concentrations of plasma NEFA76. As for
hyperketonemia, 90% of non-hyperketonemic controls showed a milk fat C18:1
cis-9-to-C15:0 ratio of 40 or lower, whereas 70% of cows suffering from hyperketonemia
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showed milk fat C18:1 cis-9-to-C15:0 ratios exceeding 40, which is consistent with our
findings of potential different trends between longer chain TGs and shorter chain TGs86.
Perhaps the higher expressed longer chain TGs in diseased animals is an early compensatory
response to reduced maternal short chain fatty acid production de novo by the udder.
As to the reduced levels of short chain fatty acid TGs seen in the PRMD susceptible
animals, this might be a foreshadowing of those particular cows having limited ability to
generate adequate amounts of their own TGs which compromises the health of the animal
as production demands remain very high at the onset of lactation.
However, in colostrum the results were quite different. The statistically significant
biomarkers in both the short chain fatty acid and longer chain fatty acid TGs were both
elevated in the colostrum of animals later developing PRMDs. Clearly colostrum production
and milk production are representative of different stages in lactation. It has been observed
that the colostrum secreted within 24 hr after calving has a distinct fat composition
compared with the secretion produced on day 4 after calving in dairy cows87. Nevertheless,
in colostrum all lipid biomarkers representative of both short chain and long chain fatty acid
TGs are significantly increased in those animals that later developed PRMDs. Given the
timing of colostrum versus milk production, the data strongly suggests that there are
preexisting problems prior to calving in those animals that later develop PRMDs that lead to
increased TGs in colostrum, and that the demands of milk production as early as day 4
postpartum deplete endogenously produced TGs quickly in animals destined to develop
PRMDs. Collectively, the data suggest that there are profoundly compromised biological
pathways that lead to or reflect PRMDs, but these remain to be identified.
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Of those markers that were part of the optimized panel, 8 out of 10 lipid biomarkers
were successfully identified. Even though it was challenging to confidently determine the
lipid class of colostrum biomarker m/z 344.2247, based on the most likely elemental
composition determined as C21H26O3+NH4 predicted by exact mass studies, it would suggest
that it is an oxidized lipid. This marker showed a higher normalized intensity in the colostrum
of case animals compared with healthy controls.
The colostrum, milk and optimized mixed panels of lipid markers described here may be
useful biomarkers for later routine application. All have shown predictive abilities with
higher than 75.0% sensitivity and specificity. The one panel optimized using linear
discriminative analysis demonstrated that there was complete separation between cows
destined to develop PRMDs and those that had an uncomplicated postpartum course. This
panel combined biomarkers from colostrum, milk and those lipids that were found in both
colostrum and milk that were significantly different in both specimens (see Figure 11).
Clearly, further confirmation needs to occur with a more focused effort on the development
of a specific risk index, i.e., the quantitative likelihood of PRMDs based on specific quantities
of the several biomarkers as part of a panel. Ideally, a single collection of colostrum and milk
with lipidomic measurement of targeted lipids could be converted into percent likelihood of
an animal developing a PRMD. Also, additional studies will need to be done surveying
broader geographic regions and different dairy breeds to confirm the effectiveness of the
current biomarkers across all dairy cows.
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Figure 11. Linear discriminative analysis of the optimal lipid biomarkers demonstrating separation between
modeled biomarker values for animals developing PRMDs later (red) and healthy control animals (blue). The
x-axis and y-axis represent the discriminant function scores.
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Chapter 4 Conclusions and future work
4.1 Summary of Bacteriophage NS01 proteomics study
Using the combination of SDS-PAGE and HPLC-MS-MS, bacteriophage NS01 proteins
were successfully characterized with high probability scores and good coverage according to
the output results from the search engine Mascot. The protein characterization approach
was a multi-step process including NS01 purification from salts, SDS gradient gel protein
separation, excised gel protein digestion with trypsin, digested protein analyzed by
HPLC-MS-MS, and further data processing with software. SDS-PAGE combined with
HPLC-MS-MS techniques helped overcome MS ion suppression issues and characterized
proteins with high confidence (p value <0.01). The hardest part of this project, however, was
purification step, which required a complete buffer exchange of the bacteriophage before
loading it onto the SDS-PAGE. This study expanded our knowledge regarding the
extremophilic virus NS01 allowing it to be categorized as a turreted T7-like virus with flexible
HK-97 subunits according to the major capsid protein gp88 secondary structure predications
as well as the putative tail protein gp86.
However, there still exist some aspects of the research that can be improved. For
example, two-dimensional gel electrophoresis (2-DE) could be used to separate proteins not
only based on their molecular weights but also on their isoelectric points, allowing for many
more bacteriophage proteins to be isolated potentially and studied. See our gel picture
Figure 4. There were 4 gel bands identified as gp91/68, gp86/78, gp72/69 and gp88/73 that
because of their similar sizes were not fully separated. However, if 2-DE had been applied,
protein isoelectric points may have helped to fully clarify more of the bacteriophage
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proteome.

4.2 Summary of biomarker study for PRMDs through a lipidomics approach
This project worked on finding and identifying predictive biomarkers for PRMDs present
in colostrum and day 4 postpartum milk using mass spectrometry through a lipidomics
approach. It successfully discovered several individual candidate lipid markers predictive of
PRMDs as well as three panels of biomarkers resulting from statistical modeling. The three
panels of biomarkers provided adequate sensitivity and specificity, all higher than 75.0%,
which would be generally acceptable for use in a real life setting.
Even though this project has shown promising results from the current three panels of
lipid markers and the individual biomarker candidates in those panels, improvements still
need to be made.
For example, internal lipid standards from diverse representative lipid groups such as
synthetic TGs could be spiked into the 2:1:1.25 chloroform:methanol: isopropanol extraction
solution as part of the lipid extraction step. If applicable, a neutral loss scan can be used for
DG and TG detection and product fragments applied for lipid quantification similar to
multiple reaction monitoring. In addition, further research can be carried out on lipids
outside the panels to chemically characterize them more completely, which may provide
more of an indication of the underlying biological pathway disturbances corresponding to
metabolic disorders in affected dairy cows.
Furthermore, in order to be an accepted dairy application, additional blinded studies
carried out at several geographic locations involving other breeds of dairy cows need to be
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carried out with the same method to validate the effectiveness of the three panels of
biomarkers. This may also require development of different biomarkers unique to different
breeds. Also, specific milk or colostrum biomarkers might be evaluated for their ability to
predict specific disease phenotypes. With even more research, one could test the response
of animals to nutritional or other interventions to determine if biomarkers normalize with
treatment and health improvement allowing for treatment assessment.
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